256 related articles for article (PubMed ID: 34006481)
1. The Impact of Genomic Profiling on Adjuvant Therapy Recommendation in Postmenopausal Women with ER-Positive, T1-2 Breast Cancer: Can Genomic Profiling Eliminate the Need for Sentinel Lymph Node Biopsy?
Lee E; Tweed C; Mylander C; Martino L; Rosman M; Huerta N; Waite K; Tafra L; Jackson RS
Clin Breast Cancer; 2021 Dec; 21(6):e731-e737. PubMed ID: 34006481
[TBL] [Abstract][Full Text] [Related]
2. How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR
Pilewskie M; Sevilimedu V; Eroglu I; Le T; Wang R; Morrow M; Braunstein LZ
Ann Surg Oncol; 2022 Oct; 29(10):6267-6273. PubMed ID: 35849294
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the Necessity for Routine Sentinel Lymph Node Biopsy in Postmenopausal Patients Being Treated for Clinically Node Negative Breast Cancer the Era of RxPONDER.
Davey MG; Kerin EP; McLaughlin RP; Barry MK; Malone CM; Elwahab SA; Lowery AJ; Kerin MJ
Clin Breast Cancer; 2023 Jul; 23(5):500-507. PubMed ID: 37076364
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound.
McEvoy AM; Poplack S; Nickel K; Olsen MA; Ademuyiwa F; Zoberi I; Odom E; Yu J; Chang SH; Gillanders WE
Breast Cancer Res Treat; 2020 Sep; 183(2):251-262. PubMed ID: 32651755
[TBL] [Abstract][Full Text] [Related]
6. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
[TBL] [Abstract][Full Text] [Related]
7. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer.
DeSnyder SM; Mittendorf EA; Le-Petross C; Krishnamurthy S; Whitman GJ; Ueno NT; Woodward WA; Kuerer HM; Akay CL; Babiera GV; Yang W; Lucci A
Clin Breast Cancer; 2018 Feb; 18(1):e73-e77. PubMed ID: 28755879
[TBL] [Abstract][Full Text] [Related]
8. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
Schwartz GF; Tannebaum JE; Jernigan AM; Palazzo JP
Cancer; 2010 Mar; 116(5):1243-51. PubMed ID: 20087958
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles in clinically T1-2N0 ER+HER2- breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed.
van Roozendaal LM; Vane MLG; Colier E; Strobbe LJA; de Boer M; Sonke G; Van Maaren MC; Smidt ML
Breast Cancer Res Treat; 2024 Jan; 203(1):103-110. PubMed ID: 37794289
[TBL] [Abstract][Full Text] [Related]
10. Can We Forgo Sentinel Lymph Node Biopsy in Women Aged ≥ 50 Years with Early-Stage Hormone-Receptor-Positive HER2-Negative Special Histologic Subtype Breast Cancer?
Knape N; Park JH; Agala CB; Spanheimer P; Morrow M; Downs-Canner S; Baldwin XL
Ann Surg Oncol; 2023 Feb; 30(2):1042-1050. PubMed ID: 36217063
[TBL] [Abstract][Full Text] [Related]
11. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.
Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM
Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919
[TBL] [Abstract][Full Text] [Related]
12. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
Damin AP; Zancan M; Melo MP; Biazus JV
Breast Cancer Res Treat; 2021 Apr; 186(2):527-534. PubMed ID: 33165710
[TBL] [Abstract][Full Text] [Related]
13. Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact.
Garcia-Tejedor A; Falo C; Fernandez-Gonzalez S; Laplana M; Gil-Gil M; Soler-Monso T; Martinez-Perez E; Calvo I; Calpelo H; Bajen MT; Benitez A; Ortega R; Petit A; Guma A; Campos M; Stradella A; Lopez-Ojeda A; Ponce J; Pla MJ; Pernas S
Breast Cancer Res Treat; 2023 Jun; 199(3):445-456. PubMed ID: 37043108
[TBL] [Abstract][Full Text] [Related]
14. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
[TBL] [Abstract][Full Text] [Related]
15. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
[TBL] [Abstract][Full Text] [Related]
16. Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient.
Franceschini G; Di Leone A; Sanchez AM; D'Archi S; Terribile D; Magno S; Scardina L; Masetti R
Ann Ital Chir; 2020; 91():465-468. PubMed ID: 32312945
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery.
Kozak MM; Horst KC; Gutkin PM; Jacobson CE; Walck E; von Eyben R; Dirbas FM
Clin Breast Cancer; 2020 Oct; 20(5):431-438. PubMed ID: 32522481
[TBL] [Abstract][Full Text] [Related]
18. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients.
El Hage Chehade H; Headon H; El Tokhy O; Heeney J; Kasem A; Mokbel K
Am J Surg; 2016 Nov; 212(5):969-981. PubMed ID: 27671032
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
Weiss A; Wong S; Golshan M; Freedman RA; Metzger O; Bellon J; Mittendorf EA; King TA
Ann Surg Oncol; 2019 Dec; 26(13):4326-4336. PubMed ID: 31562601
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial.
Sun X; Wang XE; Zhang ZP; Shi ZQ; Cong BB; Wang YS; Shao ZM
Breast Cancer Res Treat; 2020 Apr; 180(2):423-428. PubMed ID: 32034581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
